Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed Q2 revenue rises 10% to $1.3 billion; diluted EPS $2.34, up 65%

Positive Impact 3 of 5 earnings Written later

ResMed reported fiscal second-quarter 2025 results for the quarter ended December 31, 2024, with revenue up 10% to $1.3 billion and diluted earnings per share of $2.34, up from $1.42. The prior-year quarter included $64.2 million of restructuring charges, which lifts the year-over-year comparison; non-GAAP diluted EPS rose 29% to $2.43. The board also declared a quarterly dividend of $0.53 per share.

Key points

  • Revenue rose 10% to $1.3 billion ($1,282.1 million); gross margin improved 300 basis points to 58.6%.
  • Diluted EPS was $2.34 versus $1.42; non-GAAP diluted EPS was $2.43 versus $1.88.
  • Operating cash flow was $309 million; $78 million was paid in dividends and $75 million was spent on share repurchases.
  • Quarterly dividend of $0.53 per share has a February 13, 2025 record date and is payable March 20, 2025.

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECJan 30, 2025, 4:05 PM ET
Accession number0001193125-25-017218

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.